Lidorestat

• Description:

  Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation[1][2][3].

• Product Name Alternative:

  IDD-676

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Aldose Reductase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/lidorestat.html

• Purity:

  99.50

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  OC(CN1C(C=CC=C2)=C2C(CC3=NC(C(F)=C(F)C=C4F)=C4S3)=C1)=O

• Molecular Formula:

  C18H11F3N2O2S

• Molecular Weight:

  376.35

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Noh HL, et al. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther. 2009 Feb;328 (2) :496-503.|[2]Van Zandt MC, et al. Discovery of 3-[ (4,5,7-trifluorobenzothiazol-2-yl) methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. J Med Chem. 2005 May 5;48 (9) :3141-52.|[3]Maccari R, et al. Identification of new non-carboxylic acid containing inhibitors of aldose reductase. Bioorg Med Chem. 2010 Jun 1;18 (11) :4049-55.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [245116-90-9]